BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 28620004)

  • 1. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1.
    Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Schneider KW; Scott HS; Plon SE; Tabori U
    Clin Cancer Res; 2017 Jun; 23(12):e46-e53. PubMed ID: 28620004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders.
    Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Druker H; Scott HS; Tabori U
    Clin Cancer Res; 2017 Jun; 23(12):e54-e61. PubMed ID: 28620005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
    Blakeley JO; Plotkin SR
    Neuro Oncol; 2016 May; 18(5):624-38. PubMed ID: 26851632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
    Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
    Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric schwannomatosis, a rare but distinct form of neurofibromatosis.
    Thomas AK; Egelhoff JC; Curran JG; Thomas B
    Pediatr Radiol; 2016 Mar; 46(3):430-5. PubMed ID: 26546566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The path forward: 2015 International Children's Tumor Foundation conference on neurofibromatosis type 1, type 2, and schwannomatosis.
    Blakeley JO; Bakker A; Barker A; Clapp W; Ferner R; Fisher MJ; Giovannini M; Gutmann DH; Karajannis MA; Kissil JL; Legius E; Lloyd AC; Packer RJ; Ramesh V; Riccardi VM; Stevenson DA; Ullrich NJ; Upadhyaya M; Stemmer-Rachamimov A
    Am J Med Genet A; 2017 Jun; 173(6):1714-1721. PubMed ID: 28436162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofibromatosis: part 2--clinical management.
    Batista PB; Bertollo EM; Costa Dde S; Eliam L; Cunha KS; Cunha-Melo JR; Darrigo Junior LG; Geller M; Gianordoli-Nascimento IF; Madeira LG; Mendes HM; Miranda DM; Mata-Machado NA; Morato EG; Pavarino ÉC; Pereira LB; Rezende NA; Rodrigues Lde O; Sette JB
    Arq Neuropsiquiatr; 2015 Jun; 73(6):531-43. PubMed ID: 26083891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
    Ahlawat S; Blakeley JO; Langmead S; Belzberg AJ; Fayad LM
    Skeletal Radiol; 2020 Feb; 49(2):199-219. PubMed ID: 31396668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
    Friedrich RE; Nuding MA
    Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
    Fisher MJ; Belzberg AJ; de Blank P; De Raedt T; Elefteriou F; Ferner RE; Giovannini M; Harris GJ; Kalamarides M; Karajannis MA; Kim A; Lázaro C; Le LQ; Li W; Listernick R; Martin S; Morrison H; Pasmant E; Ratner N; Schorry E; Ullrich NJ; Viskochil D; Weiss B; Widemann BC; Zhu Y; Bakker A; Serra E
    Am J Med Genet A; 2018 May; 176(5):1258-1269. PubMed ID: 29681099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype-Phenotype Correlations in Neurofibromatosis and Their Potential Clinical Use.
    Bettegowda C; Upadhayaya M; Evans DG; Kim A; Mathios D; Hanemann CO;
    Neurology; 2021 Aug; 97(7 Suppl 1):S91-S98. PubMed ID: 34230207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Counseling for Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis-Practice Resource of the National Society of Genetic Counselors.
    Radtke HB; Bergner AL; Goetsch AL; McGowan C; Panzer K; Cannon A
    J Genet Couns; 2020 Oct; 29(5):692-714. PubMed ID: 32602153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optic Pathway Gliomas in Neurofibromatosis Type 1.
    Campen CJ; Gutmann DH
    J Child Neurol; 2018 Jan; 33(1):73-81. PubMed ID: 29246098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
    Ferner RE; Bakker A; Elgersma Y; Evans DGR; Giovannini M; Legius E; Lloyd A; Messiaen LM; Plotkin S; Reilly KM; Schindeler A; Smith MJ; Ullrich NJ; Widemann B; Sherman LS
    Am J Med Genet A; 2019 Jun; 179(6):1098-1106. PubMed ID: 30908866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
    Merker VL; Dai A; Radtke HB; Knight P; Jordan JT; Plotkin SR
    BMC Health Serv Res; 2018 Aug; 18(1):668. PubMed ID: 30157837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofibromatosis 1.
    Lynch TM; Gutmann DH
    Neurol Clin; 2002 Aug; 20(3):841-65. PubMed ID: 12432832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
    Ahlawat S; Fayad LM; Khan MS; Bredella MA; Harris GJ; Evans DG; Farschtschi S; Jacobs MA; Chhabra A; Salamon JM; Wenzel R; Mautner VF; Dombi E; Cai W; Plotkin SR; Blakeley JO; ;
    Neurology; 2016 Aug; 87(7 Suppl 1):S31-9. PubMed ID: 27527647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
    Merker VL; Bredella MA; Cai W; Kassarjian A; Harris GJ; Muzikansky A; Nguyen R; Mautner VF; Plotkin SR
    Am J Med Genet A; 2014 Jun; 164A(6):1431-7. PubMed ID: 24664633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic noncoding variants in the neurofibromatosis and schwannomatosis predisposition genes.
    Perez-Becerril C; Evans DG; Smith MJ
    Hum Mutat; 2021 Oct; 42(10):1187-1207. PubMed ID: 34273915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurofibromatosis type 1 and sporadic optic gliomas.
    Singhal S; Birch JM; Kerr B; Lashford L; Evans DG
    Arch Dis Child; 2002 Jul; 87(1):65-70. PubMed ID: 12089128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.